3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Carcinoma, Non-Small-Cell Lung
8
Sarcoma
5
Neoplasms
5
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Hepatocellular
2
Advanced Solid Tumors
2
Advanced Cancer
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
MSI-H or dMMR Advanced Solid Tumors
1
Lung Neoplasms
1
Leiomyosarcoma
1
Gynecological Cancer
1
Gastrointestinal Stromal Tumors
1
Gastroenteropancreatic Neuroendocrine Tumor G3
1
Fallopian Tube Neoplasms
1
Extensive Small Cell Lung Cancer
1
Esophageal Squamous Cell Carcinoma
1
Digestive System Neoplasms
1
Differentiated Thyroid Cancer
1
Interventions
pembrolizumab
44
Paclitaxel
37
Carboplatin
30
Doxorubicin
11
Cisplatin
11
Bevacizumab
11
lenvatinib
9
Nivolumab
9
Docetaxel
9
Fulvestrant
8
Gemcitabine
7
Oxaliplatin
6
Fluorouracil
6
Pemetrexed
5
Letrozole
5
Ipilimumab
5
Cetuximab
5
spartalizumab
4
selinexor
4
dostarlimab
4
Trastuzumab
4
Irinotecan
4
trastuzumab deruxtecan
3
tisotumab vedotin
3
serabelisib
3
sacituzumab govitecan
3
ribociclib
3
olaparib
3
epacadostat
3
durvalumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Endometrial Neoplasms
×
anlotinib
×
Clear all
NCT02584478
2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3
Unknown
294 enrolled
NCT02558348
2019-06-19
AL3818
Advenchen Laboratories, LLC
Phase 1/2
Terminated
12 enrolled